Peter Goodman: The Messy Reality of ‘Made in America’
The construction of a giant factory complex in Arizona was supposed to embody the Trump administration’s ability to bring manufacturing back to the United States.…
Thought Leader: Peter Goodman
How The Feds Discourage Prescription Drug Competition
July 1, 2015
Source: Link
By Scott Gottlieb (original source Forbes)
“There’s a growing refrain among those who pay for healthcare services that they want new products to deliver more value. When it comes to prescription drugs, this is usually interpreted to mean medicines that provide more benefit, at lower costs per increment of clinical advantage. Drugs that deliver more bang for the buck.
But pharmaceutical competition usually turns on claims of absolute efficacy rather than the relative and comparative merits of a medicine. There is one obvious reason.
Drug companies can rarely make claims around the value of their medicines.”
Click here to read more
Relevant and recent posts
Peter Zeihan: The Death of the US Tech Sector
We’re doing a two-part series on the tech sector. Today, we’ll be looking at the disruption caused by deglobalization and Trump’s policies. The gadgets and…
Thought Leader: Peter Zeihan
David Frum breaks down 2025’s defining moments
Leading author, journalist, and thinker David Frum and The Hub’s editor-at-large Sean Speer reflect on the most significant political developments of 2025. They discuss a…
Thought Leader: David Frum
Recent posts
Peter Goodman: The Messy Reality of ‘Made in America’
Thought Leader: Peter Goodman
Peter Zeihan: The Death of the US Tech Sector
Thought Leader: Peter Zeihan
David Frum breaks down 2025’s defining moments
Thought Leader: David Frum